Фармакоэкономический анализ применения препаратов железа у беременных с железодефицитной анемией

Aim. To study the clinical and cost efficacy of ferrous and ferric iron drugs in the treatment of iron deficiency anemia in pregnant women. Methods. In 71 women with 12 36 weeks of pregnancy and mild iron deficiency anemia conducted was determination of the level of serum iron, hemoglobin level and red blood cell count, evaluated were the morphological features of erythrocytes in the blood smear, conducted was the clinical and economical analysis by the cost effectiveness method. Results. The ferrous iron drug (ferrous sulfate + ascorbic acid) within 30 days of administration has a more pronounced effect on the dynamics of haematological parameters (increase in hemoglobin, increasing in the number of erythrocytes, the color indicator and the content of serum iron) compared with the preparation of ferric iron. According to the price of one drug package, one tablet, to the cost of a daily dose, as well as the cost of treatment for the duration of 30 days the drug ferrous sulfate + ascorbic acid is cheaper. The cost-effectiveness indicator is also the smallest in the drug ferrous sulfate + ascorbic acid. Conclusions. The drug is ferrous sulfate + ascorbic acid exhibits a high clinical efficacy, has the most optimal relationship of cost and effectiveness compared with the drug of ferric iron in the treatment of iron deficiency anemia in pregnant women.